Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Dermal translucency, Joint hypermobility, Blue sclerae, and Bruising susceptibility and others; and very common findings: Recurrent fractures. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 3 | Joint hypermobility, Joint dislocation, Recurrent fractures |
COL1A2 encodes collagen type I alpha 2 chain (1,366 aa). Type I collagen is a member of group I collagen (fibrillar forming collagen) Highest expression in Cells Cultured fibroblasts (4,674 TPM) and Artery Aorta (1,191 TPM).
Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2 is associated with mutations in the COL1A2 gene on chromosome 7.
COL1A2 is classified as a druggable target (Druggable Genome category) with score 5.8.
Genetic testing for COL1A2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 5 always present features, 1 very common feature, 4 common features.
No clinical trials have been registered for combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2.
6 publications have been identified in PubMed for combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2. Research spans Review / Meta-Analysis (67%), Case Report / Case Series (17%), and Basic Science / Preclinical (17%).
Doğan Arı AB (2026). [PMID: 41937885](https://pubmed.ncbi.nlm.nih.gov/41937885/). *Mol Syndromol*. [Basic Science / Preclinical]
Muldiiarov V (2025). [PMID: 40988516](https://pubmed.ncbi.nlm.nih.gov/40988516/). *Orthop Surg*. [Review / Meta-Analysis]
Kocsy K (2025). [PMID: 40790091](https://pubmed.ncbi.nlm.nih.gov/40790091/). *Gene Ther*. [Review / Meta-Analysis]
Manohar S (2024). [PMID: 39256175](https://pubmed.ncbi.nlm.nih.gov/39256175/). *BMJ Case Rep*. [Case Report / Case Series]
Galante N (2024). [PMID: 39008115](https://pubmed.ncbi.nlm.nih.gov/39008115/). *Int J Legal Med*. [Review / Meta-Analysis]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:41 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2
Growth and development
1 |
Short stature |
Muscles | 1 | Generalized hypotonia |
Skin | 1 | Hyperextensible skin |
Sillence DO (2024). [PMID: 38942908](https://pubmed.ncbi.nlm.nih.gov/38942908/). *Calcif Tissue Int*. [Review / Meta-Analysis]